Drugs / Veru-944
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03646162 | Sep 2018 → Apr 2020 | metastatic prostate carcinoma | Veru Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-12 | Veru Inc. | Regulatory Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy verupharma.com ↗
Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for VERU-944 (cis-clomiphene citrate). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-06-12 | Veru Inc. | Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy verupharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Veru-944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03646162 ↗ |
| Route | Oral | “placebo or VERU-944 (10 mg, 50 mg or 100 mg) orally for a total period of 12 weeks” NCT03646162 ↗ |